Monthly intravenous maintenance treatment with ustekinumab regains clinical response in patients with Crohn's disease who no longer respond to the drug when administered subcutaneously
López-Sáez, Berta (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Altadill, Ariadna (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Brunet, Eduard (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
García Sagué, Belén (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Melcarne, Luigi (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Llovet, Laura Patricia (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Frisancho, Luis Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Puy, Anna (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Lario Garcia, Sergio (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Ramirez-Lázaro, María José (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
del Estal, Jorge (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Villoria, Albert (Universitat Autònoma de Barcelona. Departament de Medicina)
Calvet, Xavier (Universitat Autònoma de Barcelona. Departament de Medicina)

Date:	2025
Abstract:	Several studies have assessed the efficacy of re-induction and subcutaneous intensification of ustekinumab (UST) to regain clinical remission of inflammatory bowel disease (IBD). However, very few have evaluated the effectiveness of intravenous UST for this purpose. The aims of the study were to evaluate the efficacy of high-dose intravenous UST (USTiv) for regaining remission in Crohn's Disease (CD) and to assess the safety of the drug. Observational, retrospective, single-center study. All patients who had received intravenous UST to regain remission until June 2023 were included. Clinical response was evaluated using the Harvey-Bradshaw Index. Drug survival was calculated using Kaplan-Meier curves. Twenty-three patients (52% female, mean age 40. 5 ± 13. 9) with CD were included. Seven (30%) patients had an incomplete primary response to UST, while 16 (70%) presented a secondary loss of response. Clinical response rates for USTiv administered monthly were 17/23 (73. 9%) at week 8, 14/23 (60. 9%) at week 16, and 10/12 (83. 3%) at 1 year. Clinical remission rates were 11/23 (47. 8%), 9/23 (39. 1%), and 8/12 (66. 7%), respectively. Median drug survival was 15. 3 ± 7. 7 months. Two patients (8%) experienced recurrent mild respiratory infections. No patients discontinued USTiv due to adverse events. More than half of the patients with CD who underwent maintenance treatment with USTiv regained clinical response after failing with subcutaneous UST treatment. No significant adverse events were observed. An alternative way to use ustekinumab for Crohn's disease patients who lose response Ustekinumab (UST) is a drug widely used to treat Crohn's Disease (CD), and it's commonly administered subcutaneously. However, some patients do not respond well enough or lose the benefits of the treatment over time. In this study, we evaluated whether switching to intravenous UST could help patients regain control of their symptoms. We reviewed data from 23 patients with CD who received this treatment at our hospital. Most had previously responded to subcutaneous UST but later experienced a loss of effectiveness. After switching to intravenous UST, more than half of the patients showed improvement at 8 and 16 weeks, and this response was maintained in many patients after one year. The treatment was generally well tolerated, and no one had to stop it because of side effects. These results suggest that intravenous UST may be a helpful option for patients with CD who no longer respond to the standard treatment.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Crohn's disease ; Inflammatory bowel disease ; Ustekinumab
Published in:	Therapeutic Advances in Gastroenterology, Vol. 18 (July 2025) , ISSN 1756-2848

DOI: 10.1177/17562848251358147
PMID: 40734661

9 p, 796.2 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles